| Autor: |
Huang, Rui, He, Honghua, Xu, Xiaoli, Lin, Xiaonan, Dong, Ying, Wang, Xiaotao, Jiang, Fang, Huang, Pengcheng, Mo, Shuyi, Huang, Zhenqian, Wang, Yaya, Tao, Hongfang, Zheng, Yaling, Wu, Ming, Yang, Chuting, Zheng, Ziyu, Zhao, Ying, Zhang, Yuming, Li, Yuhua |
| Předmět: |
|
| Zdroj: |
Cancer (0008543X); Jul2024, Vol. 130 Issue 14, p2472-2481, 10p |
| Abstrakt: |
Background: Both venetoclax plus a hypomethylating agent (VEN/HMA) and cytarabine, aclarubicin, and granulocyte colony‐stimulating factor (CAG) are low‐intensity regimens for older patients with acute myeloid leukemia (AML) that show good efficacy and safety. It is unknown how VEN/HMA compares with the CAG regimen for the treatment of newly diagnosed AML. Methods: The outcomes of patients with newly diagnosed AML treated with VEN/HMA were compared with those of patients treated with a CAG‐based regimen. Propensity score matching between these two cohorts at a 1:1 ratio was performed according to age at diagnosis, sex, Eastern Cooperative Oncology Group performance status, state of fitness, and European LeukemiaNet (ELN) 2022 risk stratification to minimize bias. Results: A total of 84 of 96 patients in the VEN/HMA cohort were matched with 84 of 147 patients in the CAG cohort. VEN/HMA resulted in a better response than the CAG‐based regimens, as indicated by a higher composite complete remission (CRc) rate (82.1% vs. 60.7%; p =.002) and minimal residual disease negativity rate (88.2% vs. 68.2%; p =.009). In patients with an ELN adverse risk, VEN/HMA was associated with a higher CRc rate compared to CAG (80.5% vs. 58.3%; p =.006). VEN/HMA was associated with longer event‐free survival (EFS) (median EFS, not reached vs. 4.5 months; p =.0004), whereas overall survival (OS) was comparable between the two cohorts (median OS, not reached vs. 18 months; p =.078). Conclusions: The VEN/HMA regimen may result in a better response than CAG‐based treatment in older patients with newly diagnosed AML. Patients newly diagnosed with acute myeloid leukemia responded better to venetoclax plus a hypomethylating agent than to cytarabine, aclarubicin, and granulocyte colony‐stimulating factor–based treatment regimens. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text